SCHEMBL30764728

SCHEMBL30764728

COc1ccc(CCCN2CC3(C2)CN(C(=O)Cc2ccc(Cl)cc2)C3)cc1

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.51
DRD2 P14416 2/20 0.50
MAPT P10636 1/20 0.50
C5AR1 P21730 1/20 0.47
ALDH1A1 P00352 3/20 0.47
HSD11B1 P28845 1/20 0.46
HPGD P15428 1/20 0.46
GHSR Q92847 2/20 0.44
CHRM2 P08172 1/20 0.44
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30764719 0.93 SMN1; SMN2 (0.53) SIGMAR1SMN1; SMN2MAPTALDH1A1HSD11B1
SCHEMBL30764720 0.89 SIGMAR1 (0.60) SIGMAR1SMN1; SMN2DRD2MAPTALDH1A1
SCHEMBL30764745 0.83 SIGMAR1 (0.53) SIGMAR1ALDH1A1HSD11B1
SCHEMBL30764706 0.82 L3MBTL1 (0.57) SIGMAR1SMN1; SMN2MAPTALDH1A1HSD11B1
SCHEMBL30764724 0.81 HSD11B1 (0.51) SMN1; SMN2ALDH1A1HSD11B1HPGDLMNA
SCHEMBL30764734 0.78 KMT2A (0.54) DRD2HSD11B1
SCHEMBL30764749 0.74 HSD11B1 (0.49) SIGMAR1MAPTHSD11B1
SCHEMBL30764755 0.74 GAA (0.54) SMN1; SMN2DRD2MAPTALDH1A1HSD11B1
SCHEMBL30764757 0.74 HSD11B1 (0.46) SMN1; SMN2ALDH1A1HSD11B1HPGDGHSR
SCHEMBL30764707 0.73 HSD11B1 (0.55) SIGMAR1SMN1; SMN2ALDH1A1HSD11B1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed